Warning: getimagesize(https://magazine.pharmamkt.net/wp-content/uploads/2020/09/logo-group.jpg): failed to open stream: HTTP request failed! HTTP/1.1 404 Not Found in /home/luciamun/public_html/magazine/wp-content/plugins/td-cloud-library/shortcodes/header/tdb_header_logo.php on line 792

The largest community of pharma leaders

PARP Inhibitors 2017

Poly (ADP-ribose) polymerase (PARP) inhibitors are targeted therapies that are used for multiple indications, most commonly, cancer. PARP aids in cellular growth, regulation and repair of cells.The PARP inhibitor stops the cancer cells being repaired which causes the cells to die thus reducing the tumor growth. Numerous cancer forms are more dependent on PARP than regular cells, making it an attractive target for cancer therapy. Currently they are used to treat ovarian cancer, fallopian tube cancer and peritoneal cancer. These inhibitors are considered as a potential treatment for acute life-threatening diseases, such as stroke and myocardial infarction, along with neurodegenerative diseases. Currently this class of drug is becoming popular which can be deduced from the increased research as seen in the below clinical trial data from past few years.

There have been around 173 studies on PARP inhibitors with 55 completed studies and 3 studies with results. Olaparib, Niraparib and Rucaparib are the commercially available PARP inhibitors.


This is commercially available as Lynparza, produced by AstraZeneca, Inc., (earlier, KuDOS Pharmaceuticals). It is used to treat ovarian cancer, fallopian tube cancer, or peritoneal cancer. It is a monotherapy used in patients with deleterious or suspected deleterious germline BRCA mutated advanced cancer who have been treated with three or more prior lines of chemotherapy. Olaparib also accounts for the highest number of clinical trials; with single drug or in combination with other molecules.


This is the second most researched PARP inhibitor. It is sold under brand name Zejula, marketed by Tesaro, Inc. (earlier developed by Merck). It is used as a maintenance treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. It is generally prescribed post chemotherapy in combination with cisplatin, oxaliplatin, carboplatin, or similar, if the patient responded to the mentioned drugs. It generated revenues of $218 million in 2016 as compared to $94 million in 2015.


It is commercialized as Rubraca, and is marketed by Clovis Oncology (earlier, Pfizer Inc.). It is the third marketed PARP inhibitor used to treat advanced ovarian cancer. It is a monotherapy for treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with 2 or more chemotherapies.

Sources: Company websites, press releases, annual reports, SEC filings, drugs.com and clinicaltrial.gov

Luca Dezzani is a Novartis employee. All the views, analysis, and perspectives are fully independent and belongs to the author only. They do not represent the views or opinions of Novartis or any other company or organization. IgeaHub is a pharmaceutical blog created and curated by Luca Dezzani.  IgeaHub does not receive any funding or support from Novartis or any other pharmaceutical company. 


Recent Articles

Asana BioSciences to Present Positive Results from Phase 2b Study of Oral JAK/SYK Inhibitor Gusacitinib in Patients with Chronic Hand Eczema in the Late-Breaking...

LAWRENCEVILLE, N.J.--(BUSINESS WIRE)--Asana BioSciences’ Oral Gusacitinib (ASN002) demonstrates rapid and significant...

Aptinyx Announces Proposed Public Offering of Common Stock

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing...

Xeris Pharmaceuticals Granted Fast Track Designation by the FDA for Its Novel Concentrated Diazepam Formulation (XP-0863) For Injection

CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging...

AppliedVR Receives FDA Breakthrough Device Designation to Treat Pain with Digital Therapeutic

LOS ANGELES--(BUSINESS WIRE)-- #chronicpain--AppliedVR, a pioneer advancing the next generation of...

After Meeting with FDA, Guided Therapeutics to Start Study in Support of its Application for FDA Approval

PEACHTREE CORNERS, Ga.--(BUSINESS WIRE)-- #FDA--After Meeting with FDA, Guided Therapeutics to...
2020 Call for Writers

Are you looking to inspire others in the pharma industry through your writing? You’re invited to submit your articles to become a Featured Writer for The Pharmaceutical Marketing Group website.